11 November 2021 
EMA/CHMP/618604/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Dengvaxia 
dengue tetravalent vaccine (live, attenuated) 
On 11 November 2021, the Committee for Medicinal Products for Human Use (CHMP) recommended 
changes to the terms of the marketing authorisation for the medicinal product Dengvaxia. The marketing 
authorisation holder for this medicinal product is Sanofi Pasteur. 
The CHMP adopted a new indication as follows:2 
Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 
2, 3 and 4 in individuals 9  6 to 45 years of age with test-confirmed previous dengue 
infection prior dengue virus infection and living in endemic areas. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after the respective decisions on 
these changes to the marketing authorisation have been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
